Breaking News Instant updates and real-time market news.

GBT

Global Blood Therapeutics

$22.50

0.2 (0.90%)

13:55
10/05/16
10/05
13:55
10/05/16
13:55

Global Blood weakness attributed to doctor questioning at panel, Bloomberg says

Shares of Global Blood Therapeutics (GBT) have slid to their worst levels of the session, which Bloomberg attributes to doctors questioning GBT400 during a panel at the Cowen conference. Global Blood shares are down 9% to $20.48 in afternoon trading.

GBT Global Blood Therapeutics
$22.50

0.2 (0.90%)

06/10/16
JANY
06/10/16
NO CHANGE
Target $71
JANY
Buy
Janney lowers bluebird bio target to $71 after 'compelling' peer data
Following new 90-day results from Global Blood Therapeutics (GBT) for its GBT440 drug in sickle cell disease patients, Janney Capital analyst Debjit Chattopadhyay said "the onus is now on" bluebird bio (BLUE) to rapidly advance process improvements in the clinic, adding that the "implications of the ASH16 data for the Lentiglobin platform cannot be understated." Based on revised market share assumptions, Chattopadhyay lowered his fair value estimate on bluebird to $71 from $91 but maintains a Buy rating on the stock.
06/13/16
LEER
06/13/16
NO CHANGE
Target $67
LEER
Outperform
bluebird can co-exist with rivals in hemoglobinopathies market, says Leerink
Leerink analyst Michael Schmidt says bluebird bio (BLUE) shares were weak on Friday following the presentation of competitor data from Global Blood Therapeutics (GBT) and Acceleron (XLRN) in sickle-cell disease and beta-thalassemia, respectively, at the European Hematology Association's congress. However, the analyst believes that given the differences between the treatment approaches and the likely different effect size and target patient population, both products could co-exist with bluebird's LentiGlobin within the hemoglobinopathies market. Schmidt reiterates an Outperform rating and $67 price target on bluebird's shares.
06/17/16
EAMC
06/17/16
NO CHANGE
Target $58
EAMC
Buy
Global Blood Therapeutics GBT440 data is promising, says Empire
Empire analyst Dr. Cathy Reese said GBT440's EHA 2016 Phase I/II data presented on June 10 at the the European Hematology Association's 2016 annual meeting in Copenhagen, Denmark looks promising. Reese said the single center data in 27 patients provides reassurance that GBT440 has potential to be a successful therapy for SCD patients. While the GBT440 data was from an early-stage trial and in a limited number of patients, GBT440 seemed to demonstrate a relatively steady improvement in the patients' hemolysis markers and exhibited acceptable tolerability. The next step in GBT440's development should be a meeting with the FDA this summer to begin to formulate the next clinical development steps for the drug. Dr. Reese rates Global Blood a Buy with a $58 price target on shares.
09/30/16
WELS
09/30/16
INITIATION
WELS
Outperform
Global Blood Therapeutics initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Global Blood Therapeutics with an Outperform rating and $75-$81 price target range. The analyst has a positive outlook for the company's hemoglobin modifier GBT440 in Sickle Cell Disease. He views GBT440 as a best-in-class hemoglobin modifier and estimates peak sales at $2.7B.

TODAY'S FREE FLY STORIES

ADM

Archer Daniels

$40.61

0.13 (0.32%)

, BG

Bunge

$69.78

0.14 (0.20%)

16:03
01/19/18
01/19
16:03
01/19/18
16:03
Periodicals
Archer Daniels made takeover approach to Bunge, WSJ says »

Archer Daniels Midland…

ADM

Archer Daniels

$40.61

0.13 (0.32%)

BG

Bunge

$69.78

0.14 (0.20%)

GLNCY

Glencore

$11.29

-0.02 (-0.18%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

C

Citi

$78.16

0.77 (0.99%)

16:01
01/19/18
01/19
16:01
01/19/18
16:01
Conference/Events
Citigroup to hold a conference call »

CFO Gerspach and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 24

    Jan

GOLF

Acushnet Holdings

$21.50

0.65 (3.12%)

16:01
01/19/18
01/19
16:01
01/19/18
16:01
Hot Stocks
Acushnet Holdings acquires Linkgs & Kings, terms not disclosed »

Acushnet Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BG

Bunge

$69.79

0.145 (0.21%)

, ADM

Archer Daniels

$40.66

0.18 (0.44%)

15:58
01/19/18
01/19
15:58
01/19/18
15:58
Hot Stocks
Breaking Hot Stocks news story on Bunge, Archer Daniels »

Bunge jumps 10% after…

BG

Bunge

$69.79

0.145 (0.21%)

ADM

Archer Daniels

$40.66

0.18 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

BG

Bunge

$69.76

0.12 (0.17%)

, ADM

Archer Daniels

$40.66

0.18 (0.44%)

15:57
01/19/18
01/19
15:57
01/19/18
15:57
Periodicals
Breaking Periodicals news story on Bunge, Archer Daniels »

Archer Daniels made…

BG

Bunge

$69.76

0.12 (0.17%)

ADM

Archer Daniels

$40.66

0.18 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 14

    Feb

HGT

Hugoton Royalty Trust

15:57
01/19/18
01/19
15:57
01/19/18
15:57
Hot Stocks
Breaking Hot Stocks news story on Hugoton Royalty Trust »

Hugoton Royalty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSA

Comcast

$41.85

0.17 (0.41%)

15:50
01/19/18
01/19
15:50
01/19/18
15:50
Options
Bullish option play in Comcast ahead of earnings next week »

Bullish option play in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

SLB

Schlumberger

$76.33

-0.0384 (-0.05%)

15:35
01/19/18
01/19
15:35
01/19/18
15:35
Recommendations
Schlumberger analyst commentary  »

Schlumberger price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

HGT

Hugoton Royalty Trust

15:35
01/19/18
01/19
15:35
01/19/18
15:35
Hot Stocks
Breaking Hot Stocks news story on Hugoton Royalty Trust »

Hugoton Royalty Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVGO

Broadcom

$269.80

3.99 (1.50%)

, QCOM

Qualcomm

$68.05

0.03 (0.04%)

15:31
01/19/18
01/19
15:31
01/19/18
15:31
Periodicals
FTC in place to make second request over Broadcom's Qualcomm bid, Reuters says »

The U.S. Federal Trade…

AVGO

Broadcom

$269.80

3.99 (1.50%)

QCOM

Qualcomm

$68.05

0.03 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Mar

A

Agilent

$73.00

0.81 (1.12%)

15:30
01/19/18
01/19
15:30
01/19/18
15:30
Options
Agilent attracts a vote of confidence as shares reach 17-year highs »

Agilent attracts a vote…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$43.80

0.5 (1.15%)

15:23
01/19/18
01/19
15:23
01/19/18
15:23
Conference/Events
FB Financial management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ASNA

Ascena Retail

$2.11

-0.01 (-0.47%)

15:20
01/19/18
01/19
15:20
01/19/18
15:20
Options
Ascena Retail attracts upside call buying »

Ascena Retail attracts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:18
01/19/18
01/19
15:18
01/19/18
15:18
Conference/Events
RBC Capital equity strategy analyst holds luncheon meeting »

Equity Strategy Analyst…

$NSD

NASDAQ Market Internals

15:17
01/19/18
01/19
15:17
01/19/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
01/19/18
01/19
15:16
01/19/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IWM

iShares Trust Russell 2000 Index Fund

$158.42

1.88 (1.20%)

, RUT

Russell 2000 Index

15:14
01/19/18
01/19
15:14
01/19/18
15:14
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

At time of writing the…

IWM

iShares Trust Russell 2000 Index Fund

$158.42

1.88 (1.20%)

RUT

Russell 2000 Index

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKTX

Akari Therapeutics

$3.60

-0.17 (-4.51%)

15:08
01/19/18
01/19
15:08
01/19/18
15:08
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

XLY

Consumer Discretionary Sector SPDR

$105.56

0.8668 (0.83%)

, XLV

Health Care Select Sector SPDR

$88.26

0.151 (0.17%)

15:05
01/19/18
01/19
15:05
01/19/18
15:05
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX) is…

XLY

Consumer Discretionary Sector SPDR

$105.56

0.8668 (0.83%)

XLV

Health Care Select Sector SPDR

$88.26

0.151 (0.17%)

XLE

Energy Select Sector SPDR

$76.30

-0.1821 (-0.24%)

XLK

Technology Select Sector SPDR

$67.69

0.015 (0.02%)

XLI

Industrial Select Sector SPDR

$79.64

0.1772 (0.22%)

XLU

Utilities SPDR

$49.99

-0.15 (-0.30%)

XLP

Consumer Staples Sector SPDR

$58.01

0.615 (1.07%)

SPY

SPDR S&P 500 ETF Trust

$280.02

0.875 (0.31%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JOUT

Johnson Outdoors

$62.61

-0.71 (-1.12%)

15:04
01/19/18
01/19
15:04
01/19/18
15:04
Initiation
Johnson Outdoors initiated  »

Johnson Outdoors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

EPC

Edgewell Personal Care

$58.26

-1.725 (-2.88%)

15:00
01/19/18
01/19
15:00
01/19/18
15:00
Options
Bearish flow in Edgewell Personal Care as shares see relative weakness »

Bearish flow in Edgewell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Feb

15:00
01/19/18
01/19
15:00
01/19/18
15:00
General news
Treasury Closing Summary: »

Treasury Closing…

SPY

SPDR S&P 500 ETF Trust

$280.05

0.91 (0.33%)

, SPX

S&P 500

14:53
01/19/18
01/19
14:53
01/19/18
14:53
Periodicals
No deal after Trump, Schumer meeting, Fox News' Pergram says »

Chad Pergram, who covers…

SPY

SPDR S&P 500 ETF Trust

$280.05

0.91 (0.33%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$19.94

0.54 (2.78%)

14:50
01/19/18
01/19
14:50
01/19/18
14:50
Options
Aggressive upside call buying in Freeport McMoran ahead of earnings next week »

Aggressive upside call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

RIG

Transocean

$11.46

0.135 (1.19%)

14:45
01/19/18
01/19
14:45
01/19/18
14:45
Options
Transocean call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.